Investing.com - Financial Markets Worldwide

Merus NV stock hits all-time high at 94.56 USD

Published 09/10/2025, 19:52
Merus NV stock hits all-time high at 94.56 USD
MRUS
-0.22%

Merus NV stock has reached a significant milestone, hitting an all-time high of $94.56, pushing its market capitalization to $7.2 billion. This achievement underscores the company’s strong performance over the past year, during which its stock price has surged by 79.49%. According to InvestingPro data, the company maintains a "GOOD" financial health score, though technical indicators suggest the stock is currently overbought. The biotechnology firm has been on an upward trajectory, reflecting investor confidence and positive market sentiment, with revenue growth of nearly 60% in the last twelve months. This latest peak marks a new chapter for Merus NV, as it continues to build on its growth momentum and explore further opportunities in the biotech industry. Based on InvestingPro’s Fair Value analysis, the stock appears overvalued at current levels. Discover 16 additional key insights and a comprehensive Pro Research Report available exclusively on InvestingPro.

In other recent news, Merus N.V. has been the subject of significant developments, particularly due to its acquisition by Genmab. The transaction, valued at approximately $8 billion, involves an all-cash offer of $97 per share, representing a premium of about 40% over Merus’s previous market value. This acquisition is expected to close in the early first quarter of 2026. Following the announcement, several analyst firms have adjusted their ratings for Merus. Leerink Partners downgraded the stock from Outperform to Market Perform, while Barclays shifted its rating from Overweight to Equalweight, citing valuation concerns. Guggenheim also downgraded Merus from Buy to Neutral and reduced its price target. UBS followed suit, downgrading the stock from Buy to Neutral, although it raised the price target to $97. These rating changes reflect the analysts’ reassessment of Merus’s valuation post-acquisition announcement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.